This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
It was not apparent from the study whether the sample size was determined in the planning phase, and no power calculations were performed. The study included a cohort of 356 consecutive patients with a histological diagnosis of CIN1 that was based on punch biopsies. The mean age of the patients was 34 (+/-3) years (range: 16 -52). All patients had been referred to the Cervical Pathology Unit from several women's health centres. The analysis included 314 (88.2%) of the 356 referrals who met the inclusion criteria.
Study design
Initially, the authors conducted a prospective study using repeated cytology as the sole parameter for triaging patients with histologic definition of CIN1 for further colposcopic evaluation. The analysis of HPV status of the same 314 participants was conducted retrospectively. The women were referred to the Cervical Pathology Unit from several women's health centres. The mean duration of follow-up was 29 months. The patients were followed up by Pap smears at 6-month intervals. Separate samples for the HPV tests were obtained before the Pap smears, and were taken on the first visit to the authors' institution. The authors mentioned that the clinicians caring for the patients were blinded to the results of the HPV testing until the conclusion of the trial, but the blinding method was not reported in detail. The authors did not report any losses to follow-up.
Analysis of effectiveness
From the initial study population, 42 patients were excluded for not fulfilling the inclusion criteria. The remaining 314 patients were all included in the analysis. The primary outcome was the positive predictive value (PPV) of low-grade squamous intraepithelial lesion (LSIL) to identify cases of CIN1 and of HSIL to identify cases of CIN2-3, for each of the two screening strategies. In the study there were two interventions, cytology and HPV DNA testing. These were each investigated prospectively and retrospectively on the same group of patients.
Effectiveness results
For normal cytology, the PPV of LSIL to CIN1 was 48.9% (22 cases). The PPV of HSIL to CIN2-3 was 95%. The PPV of LSIL for any type of CIN was 62% (28 cases).
For the HPV approach, a positive HPV with normal cytology had a 95.2% PPV for any type of CIN. The PPV of lowrisk PHV type for CIN1 and that of high-risk HPV type for CIN2-3 were both 97%.
Of the 314 study participants, 68 (21.6%) were positive for the HPV analysis. Sixty-seven of these (98.5%) had either CIN1 or CIN2-3 on the cone biopsy, with an overall PPV of 95%.
In addition, no patient with a negative HPV had any grade of CIN. Of the 34 cases with high-risk HPV types, 33 had CIN2-3 on the cone biopsy, yielding a PPV of 97%. The PPV of low-risk HPV type for CIN1 was 97%.
Clinical conclusions
The authors concluded that, although the addition of HPV testing to the follow-up of patients with a histologic diagnosis of CIN1 did not have much benefit for patients with a cytological report of HSIL, it reduced the rate of false-negative cases, especially among patients with persistent normal cytology. It also increased the detection rate of patients who were at high risk of progressing to high-grade lesions (CIN2-3), and reduced the number of referrals for colposcopy and unnecessary biopsies without affecting diagnostic accuracy.
Measure of benefits used in the economic analysis
The authors considered cases of high-grade intraepithelial lesion detected as the most appropriate measure to be included in the economic analysis.
